{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:48:48Z","timestamp":1790711328979,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.chest.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T10:24:43Z","timestamp":1627122283000},"page":"64-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Treatment of Mycobacterium abscessus Pulmonary Disease"],"prefix":"10.1016","volume":"161","author":[{"given":"David E.","family":"Griffith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1513\/AnnalsATS.201412-559OC","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2021.07.035_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.035_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1513\/AnnalsATS.201501-015OI","article-title":"Mycobacterium abscessus. \"Pleased to meet you, hope you guess my name\u2026\"","volume":"12","author":"Griffith","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.chest.2021.07.035_bib4","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5588\/ijtld.14.0134","article-title":"Advances in the management of pulmonary disease due to Mycobacterium abscessus complex","volume":"18","author":"Koh","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.chest.2021.07.035_bib6","series-title":"Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management","first-page":"369","article-title":"Disease caused by Mycobacterium abscessus and other rapidly growing mycobacteria","author":"Philley","year":"2019"},{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib7","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1378\/chest.14-1297","article-title":"The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy","volume":"147","author":"Griffith","year":"2015","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A\u00a0novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.chest.2021.07.035_bib9","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dks279","article-title":"Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41)","volume":"67","author":"Maurer","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.chest.2021.07.035_bib10","series-title":"Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management","first-page":"15","article-title":"Laboratory diagnosis and antimicrobial susceptibility testing of nontuberculous mycobacteria","author":"Brown","year":"2019"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/JCM.02950-14","article-title":"Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs","volume":"53","author":"Brown-Elliott","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"3","key":"10.1016\/j.chest.2021.07.035_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2021.07.035_bib13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.rmed.2014.09.002","article-title":"A\u00a0shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease","volume":"108","author":"Lyu","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.035_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jcf.2014.07.004","article-title":"Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients","volume":"14","author":"Roux","year":"2015","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chest.2021.07.035_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cid\/ciw723","article-title":"Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense","volume":"64","author":"Park","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.chest.2021.07.035_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02189-16","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease","volume":"61","author":"Choi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2017.12.008","article-title":"Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease","volume":"90","author":"Choi","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01146-17","article-title":"Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease","volume":"61","author":"Choi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.chest.2021.07.035_bib19","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.chest.2016.05.003","article-title":"Oral macrolide therapy following short-term combination antibiotic treatment of Mycobacterium massiliense lung disease","volume":"150","author":"Koh","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.07.035_bib20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.chest.2016.07.015","article-title":"Nontuberculous mycobacterial disease therapy: take it to the limit one more Time","volume":"150","author":"Griffith","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [published correction appears in Am J Respir Crit Care Med. 2007;175(7):744-745]","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.chest.2021.07.035_bib23","doi-asserted-by":"crossref","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.chest.2021.07.035_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"issue":"suppl 1","key":"10.1016\/j.chest.2021.07.035_bib25","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"suppl 2","key":"10.1016\/j.chest.2021.07.035_bib26","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.chest.2021.07.035_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial susceptibility testing of nontuberculous mycobacteria","volume":"57","author":"Brown-Elliott","year":"2019","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.chest.2021.07.035_bib30","series-title":"Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Diagnosis and Management","first-page":"61","article-title":"Drug susceptibility testing for nontuberculous mycobacteria","author":"van Ingen","year":"2019"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib31","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In\u00a0vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.chest.2021.07.035_bib32","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2021.07.035_bib33","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2021.07.035_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1164\/rccm.201810-1901ED","article-title":"ALIS (Amikacin Liposome Inhalation Suspension): the beginning of a wonderland?","volume":"198","author":"Daley","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.07.035_bib35","doi-asserted-by":"crossref","unstructured":"Siegel SAR, Brown-Elliott BA, Strnad L, et\u00a0al. Evaluation of antimicrobial susceptibility to amikacin liposome inhalation suspension and relapse\/reinfection in pulmonary M. Abscessus disease. Paper presented at the American Thoracic Society meeting; May 2020; Philadelphia, PA.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4495"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.07.035_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.035_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","article-title":"Efficacy and safety of tigecycline for Mycobacterium abscessus disease","volume":"158","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2021.07.035_bib40","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/jac\/dku062","article-title":"Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections","volume":"69","author":"Wallace","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.chest.2021.07.035_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01919-18","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex","volume":"63","author":"Brown-Elliott","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.chest.2021.07.035_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.07.035_bib43","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In\u00a0vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib44","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.chest.2021.07.035_bib53","doi-asserted-by":"crossref","first-page":"ofaa415","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for\u00a0the Treatment of Mycobacterium abscessus Disease: A\u00a0Case\u00a0Series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.chest.2021.07.035_bib54","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.chest.2021.07.035_bib45","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3389\/fmicb.2018.02273","article-title":"Mycobacterium abscessus and \u03b2-lactams: emerging insights and potential opportunities","volume":"9","author":"Story-Roller","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.chest.2021.07.035_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02895-18","article-title":"Dual \u03b2-lactam combinations highly active against Mycobacterium abscessus complex in\u00a0vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.chest.2021.07.035_bib47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.chest.2021.07.035_bib48","doi-asserted-by":"crossref","first-page":"1702127","DOI":"10.1183\/13993003.02127-2017","article-title":"Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis","volume":"51","author":"Scott","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.chest.2021.07.035_bib50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/17460441.2019.1629414","article-title":"Repositioning rifamycins for Mycobacterium abscessus lung disease","volume":"14","author":"Ganapathy","year":"2019","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"10.1016\/j.chest.2021.07.035_bib51","doi-asserted-by":"crossref","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","article-title":"Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course","volume":"49","author":"Hwang","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2021.07.035_bib52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/ciq252","article-title":"The talking Mycobacterium abscessus blues","volume":"52","author":"Griffith","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221013702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221013702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:01:59Z","timestamp":1762124519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221013702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0012369221013702"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.035","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Mycobacterium abscessus Pulmonary Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}